

COMPANY ANNOUNCEMENT**6 August 2010****ADDITIONAL BOARD CHANGES**

NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience drug development company, today announces additional changes to the Board following shareholder approval for the sale of UK-based NeuroSolutions Ltd as announced on 22 July 2010.

Mr David McAuliffe, has today resigned as Executive Director of the Company. Mr McAuliffe remains as a consultant to the Company and has been tasked to ensure further development and potential commercialisation of NSL-101 whilst also seeking potential licensing opportunities for the Company. Mr McAuliffe remains a large and committed shareholder of the Company.

The Company has also today appointed Mr Neville Bassett as a Non-Executive Director.

Mr Bassett is a Chartered Accountant operating his own corporate consulting business, specialising in the area of corporate, financial and management advisory services. Mr Bassett consults to a number of publicly listed companies and private company groups in a diversity of industry sectors. He is a director or company secretary of a number of public and private companies.

Mr Bassett has been involved with numerous public company listings and capital raisings. His involvement in the corporate arena has also taken in mergers and acquisitions, and includes significant knowledge and exposure to the Australian financial markets. Mr Bassett has a wealth of experience in matters pertaining to the Corporations Act, ASX listing requirements, corporate taxation and finance.

Harry Karelis – Non Executive Chairman
T: +61 (0)413 056 328
E: hkarelis@titanbioventures.com

-ENDS-**About NeuroDiscovery**

NeuroDiscovery Ltd is an ASX listed speciality neuroscience drug development company (ASX Code NDL).